Evolus, Inc. (EOLS)

NGM – Real vaqt narxi. Valyuta: USD

7.13

-0.02 (-0.28%)

Yopilishda: Jun 26, 2026, 4:00 PM EDT

7.13

0.00 (0.00%)

Bozordan keyin: Jun 26, 2026, 4:43 PM EDT

19.05.2026

Evolus to Participate in The Jefferies Global Healthcare Conference

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced members of its management team will participate in a fireside chat and investor meetings at the upcoming Jefferies Global Healthcare Conference in New York City. The fireside chat will take place on Thursday, June 4th, 2026, at 12:50 PM ET. The fireside chat can be accessed on the Investor Relations page of the Evol.

11.05.2026

Evolus Announces Commercial Launch of Estyme® Injectable Hyaluronic Acid Gels in Europe

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that the commercial launch of Estyme® (pronounced “esteem”), its injectable hyaluronic acid (HA) gel collection in Europe, is scheduled for May 16th, marking the company's entry into the international dermal filler market. The Estyme® collection includes four injectable HA gels that will cover a wide range of.

05.05.2026

Evolus, Inc. (EOLS) Q1 2026 Earnings Call Transcript

05.05.2026

Evolus, Inc. (EOLS) Reports Q1 Loss, Tops Revenue Estimates

Evolus, Inc. (EOLS) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to a loss of $0.18 per share a year ago.

04.05.2026

Evolus Reports First Quarter 2026 Financial Results; Company Delivers Second Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year Outlook

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced its financial results for the first quarter ended March 31, 2026. “We started 2026 with a second consecutive quarter of positive Adjusted EBITDA, delivering profitability1 in what is seasonally our lowest revenue quarter,” said David Moatazedi, President and Chief Executive Officer of Evolus. “This performanc.

04.05.2026

Weight-loss revolution sparks new appetite for aesthetics firms

Aesthetic firms are betting that a growing pool of patients experiencing loose skin and facial volume loss from GLP-1 obesity drugs will fuel a new wave of demand, as the sector heads into first-quarter earnings this week.

14.04.2026

Evolus to Report First Quarter Financial Results on May 4, 2026

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its first quarter 2026 financial results on Monday, May 4, 2026, after the U.S. financial markets close. Evolus management will host a conference call and live webcast to discuss these results at 4:30 p.m. ET that same day. A question-and-answer session will follow management's remarks. To partic.

Videolar

No Data

There is no data to display

Press-relizlar

11.05.2026

Evolus Announces Commercial Launch of Estyme® Injectable Hyaluronic Acid Gels in Europe

04.05.2026

Evolus Reports First Quarter 2026 Financial Results; Company Delivers Second Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year Outlook

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced its financial results for the first quarter ended March 31, 2026. “We started 2026 with a second consecutive quarter of positive Adjusted EBITDA, delivering profitability1 in what is seasonally our lowest revenue quarter,” said David Moatazedi, President and Chief Executive Officer of Evolus. “This performanc.

31.03.2026

Evolus to Participate in the Needham 25th Annual Virtual Healthcare Conference

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced members of its management team will participate in a fireside chat and investor meetings at the upcoming Needham Virtual Healthcare Conference. The fireside chat will take place on Tuesday, April 14, 2026, at 3:45 PM ET. The fireside chat can be accessed on the Investor Relations page of the Evolus website here. A r.

20.03.2026

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS) a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant during March 2026 of an aggregate of 85,516 restricted stock units (RSUs) and 8,635 stock options of the company's common stock to 10 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the company's board of directors under the Evolus' 2023 Inducemen.

Evolus, Inc. (EOLS)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Evolus, Inc. (EOLS)

Evolus to Participate in The Jefferies Global Healthcare Conference

Evolus Announces Commercial Launch of Estyme® Injectable Hyaluronic Acid Gels in Europe

Evolus, Inc. (EOLS) Q1 2026 Earnings Call Transcript

Evolus, Inc. (EOLS) Reports Q1 Loss, Tops Revenue Estimates

Evolus Reports First Quarter 2026 Financial Results; Company Delivers Second Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year Outlook

Weight-loss revolution sparks new appetite for aesthetics firms

Evolus to Report First Quarter Financial Results on May 4, 2026

Videolar

No Data

Press-relizlar

Evolus Announces Commercial Launch of Estyme® Injectable Hyaluronic Acid Gels in Europe

Evolus Reports First Quarter 2026 Financial Results; Company Delivers Second Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year Outlook

Evolus to Participate in the Needham 25th Annual Virtual Healthcare Conference

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Evolus to Participate in The Jefferies Global Healthcare Conference

Evolus Announces Commercial Launch of Estyme® Injectable Hyaluronic Acid Gels in Europe

Evolus, Inc. (EOLS) Q1 2026 Earnings Call Transcript

Evolus, Inc. (EOLS) Reports Q1 Loss, Tops Revenue Estimates

Evolus Reports First Quarter 2026 Financial Results; Company Delivers Second Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year Outlook

Weight-loss revolution sparks new appetite for aesthetics firms

Evolus to Report First Quarter Financial Results on May 4, 2026

Videolar

No Data

Press-relizlar

Evolus Announces Commercial Launch of Estyme® Injectable Hyaluronic Acid Gels in Europe

Evolus Reports First Quarter 2026 Financial Results; Company Delivers Second Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year Outlook

Evolus to Participate in the Needham 25th Annual Virtual Healthcare Conference

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Search stocks

Evolus, Inc. (EOLS)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Evolus, Inc. (EOLS)

Evolus to Participate in The Jefferies Global Healthcare Conference

Evolus Announces Commercial Launch of Estyme® Injectable Hyaluronic Acid Gels in Europe

Evolus, Inc. (EOLS) Q1 2026 Earnings Call Transcript

Evolus, Inc. (EOLS) Reports Q1 Loss, Tops Revenue Estimates

Evolus Reports First Quarter 2026 Financial Results; Company Delivers Second Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year Outlook

Weight-loss revolution sparks new appetite for aesthetics firms

Evolus to Report First Quarter Financial Results on May 4, 2026

Videolar

No Data

Press-relizlar

Evolus Announces Commercial Launch of Estyme® Injectable Hyaluronic Acid Gels in Europe

Evolus Reports First Quarter 2026 Financial Results; Company Delivers Second Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year Outlook

Evolus to Participate in the Needham 25th Annual Virtual Healthcare Conference

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Evolus to Participate in The Jefferies Global Healthcare Conference

Evolus Announces Commercial Launch of Estyme® Injectable Hyaluronic Acid Gels in Europe

Evolus, Inc. (EOLS) Q1 2026 Earnings Call Transcript

Evolus, Inc. (EOLS) Reports Q1 Loss, Tops Revenue Estimates

Evolus Reports First Quarter 2026 Financial Results; Company Delivers Second Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year Outlook

Weight-loss revolution sparks new appetite for aesthetics firms

Evolus to Report First Quarter Financial Results on May 4, 2026

Videolar

No Data

Press-relizlar

Evolus Announces Commercial Launch of Estyme® Injectable Hyaluronic Acid Gels in Europe

Evolus Reports First Quarter 2026 Financial Results; Company Delivers Second Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year Outlook

Evolus to Participate in the Needham 25th Annual Virtual Healthcare Conference

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)